Rising Biosciences (Rising Biosciences) Other Current Liabilities : $0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Other Current Liabilities?

Rising Biosciences's other current liabilities for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Other Current Liabilities Historical Data

The historical data trend for Rising Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Other Current Liabilities Chart

Rising Biosciences Annual Data

Trend

Other Current Liabilities

Rising Biosciences Quarterly Data

Other Current Liabilities

Rising Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Rising Biosciences Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Other Current Liabilities

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.